Seres Therapeutics
MCRB
45 hedge funds and large institutions have $471M invested in Seres Therapeutics in 2015 Q2 according to their latest regulatory filings, with 45 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$229M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$41.9M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$28.3M |
| 4 |
FV2GP
Flagship Ventures 2007 General Partner
Cambridge,
Massachusetts
|
+$26.1M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
+$17.9M |
Top Sellers
MCRB Hedge Fund Activity: Q2 2015 in Review
45 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q2 2015, worth a combined $471M.
Buyers outnumbered sellers: 45 funds opened new MCRB positions and 0 closed out — a net gain of 45 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $229M.
- 45 institutional investors held Seres Therapeutics (MCRB) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $471M of Seres Therapeutics stock for Q2 2015.
- 45 funds opened new Seres Therapeutics positions in Q2 2015 and 0 closed out, a net change of +45 holders.
- The largest Seres Therapeutics buyer in Q2 2015 was Fidelity Investments, an estimated $229M added.
Based on aggregated 13F filings for Q2 2015.